Associate Professor of Medicine Medical Director, Gastrointestinal Oncology Director, Mesothelioma Program
Hematology
Dr. Hedy L. Kindler, MD
Hedy Kindler works in the field of Hematology. She graduated from Albert Einstein College of Medicine. She over the years received 5 awards: "America's Top Doctors", "Chicago Magazine: Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer" and "Super Doctor". Hedy Kindler is also a published doctor. She has 81 publication published. The most recent publication is: Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Hedy L. Kindler is registered with Medicare and accepts Medicare payments.
Publications
- Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe CytoreDuctive Surgery in the Elderly.
- Radiologic-pathologic correlation of mesothelioma tumor volume.
- Generalizability of trial results to elderly Medicare patients with advanced solid Tumors (Alliance 70802).
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
- Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced Malignant pleural mesothelioma.
- AntiCancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance).
- The vulnerable elders survey-13 predicts mortality in older adults with later-stage colorectal Cancer receiving chemotherapy: a prospective pilot study.
- Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance.
- Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic AdenoCarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor.
- Variability of tumor area measurements for response assessment in Malignant pleural mesothelioma.
- Immunological effects of the TGFβ-blocking antibody GC1008 in Malignant pleural mesothelioma patients.
- MARS: A Sense of Perspective and an Inconvenient Truth.
- Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
- Disease volumes as a marker for patient response in Malignant pleural mesothelioma.
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design.
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic c...
- Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report.
- Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
- A genome-wide association study of overall survival in pancreatic Cancer patients treated with gemcitabine in CALGB 80303.
- RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenoCarcinoma.
- Surgery for mesothelioma? The debate continues.
- Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (cancer and Leukemia group B 80303).
- Dasatinib in previously treated metastatic colorectal Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Personalized colon Cancer care in 2010.
- Quantitative measurement of Lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.
- Update on Malignant pleural mesothelioma.
- Computerized segmentation and measurement of Malignant pleural mesothelioma.
- Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic coloRectal carcinoma.
- The epothilone B analogue ixabepilone in patients with advanced hepatobiliary Cancers: a trial of the University of Chicago Phase II Consortium.
- A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
- Gemcitabine plus sorafenib in patients with advanced pancreatic Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CA...
- A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenoCarcinoma.
- Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancr...
- Malignant pleural mesothelioma: an update on biomarkers and treatment.
- Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for Malignant pleural mesothelioma.
- A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient Cancer.
- Arsenic trioxide in patients with adenoCarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
- Erlotinib plus bevacizumab in previously treated patients with Malignant pleural mesothelioma.
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Systemic treatments for mesothelioma: standard and novel.
- Association between bone marrow dosimetric parameters and Acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulat...
- A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal Cancer hepatic metastases: Cancer...
- Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal Cancer: the BOND-...
- Phase I and pharmacokinetic study of erlotinib for solid Tumors in patients with hepatic or renal dysfunction: CALGB 60101.
- A review of resistance patterns and phenotypic changes in gastrointestinal stromal Tumors following imatinib mesylate therapy.
- Pancreatic Cancer: an update.
- The cancer and Leukemia group B respiratory committee.
- Variability in mesothelioma tumor response classification.
- Functional Analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
- Antiangiogenic therapies for mesothelioma.
- Front-line therapy of advanced pancreatic Cancer.
- Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic Cancer.
- Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
- Phase II trials of dolastatin-10 in advanced pancreaticobiliary Cancers.
- Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal Cancer.
- Chemotherapy for advanced pancreatic Cancer: past, present, and future.
- In focus: advanced pancreatic Cancer.
- A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree Carcinoma.
- DeLivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
- Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine Tumors.
- 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenoCarcinomas of the stomach and gastroesophageal junction: A phase II t...
- Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
- A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid Tumors.
- The emerging role of pemetrexed for the treatment of Malignant mesothelioma.
- Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
- Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
- Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in Malignant pleural mesothelioma.
- Pemetrexed in pancreatic Cancer.
- The pemetrexed/gemcitabine combination in pancreatic Cancer.
- Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin...
- Pemetrexed in patients with gastrointestinal Carcinoma.
- New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
- The role of gemcitabine in the treatment of Malignant mesothelioma.
- Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced Cancer.
- Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance).
- Considering the role of radiation therapy for gastrointestinal stromal tumor.
- Current controversies in the stage-specific multidisciplinary management of pancreatic Cancer.
- MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma.
Schools
University At Buffalo State University Of New York School Of Medicine
A Einstein College M Yeshiva University
Mem Sloan Kettering Cancer Center
UCLA Med Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Memorial Sloan-Kettering Cancer Center -
Albert Einstein College of Medicine -
UCLA Medical Center -
University at Buffalo, School of Medicine and Biomedical Sciences
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1851453302 | |
| NPPES Provider LastName | KINDLER | |
| NPPES Provider FirstName | HEDY | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 102.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851453302 |
| Last Name Of The Provider | KINDLER |
| First Name Of The Provider | HEDY |
| View All |
Similar Doctors
|
Dr. Gini F. Fleming, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harvey M. Golomb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph M. Baron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James E. Hannigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas F. Gajewski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Richard L. Schilsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olatoyosi Odenike, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucy A. Godley, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Olufunmailyao Olopade, MD |
|
|
Dr. Ezra E. Cohen, MD |
|
|
Brittany Beach
This Doctor is OpenDoctor Recommended.
|